Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABN401 Monotherapy and Combination with Lazertinib in c-MET Dysregulated Advanced Solid Tumors
NCT05541822Phase 2Recruiting
- Sponsor
- ABION Inc.
- Start
- Jan 2023
- Primary completion
- Feb 2029
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of vabametkib in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by ABION Inc. Primary endpoints: Objective Response Rate up to 12 months, Incidence of Dose Limiting Toxicity up to 12 months and 1 more. Started Jan 2023; status: recruiting.
02
Drugs
vabametkib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05541822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05541822.